HDClarity

Recruiting

LEARN MORE

SPONSOR

CHDI Foundation, Inc.

PARTICIPANTS

1200

HDClarity is aiming to collect high quality cerebrospinal fluid (CSF) samples. Along with matching high quality plasma samples.

This will allow researchers  to better evaluate  biomarkers and pathways that will help with the development of new treatments for Huntington’s disease (HD).

Subtype: Observational Biomarker

Ages Eligible
for Study:

21 Years to 75 Years

(Adult, Older Adult)

Sexes Eligible
for Study:

All

Accepts Healthy Volunteers:

Yes

All eligible participants:
a) Are 21-75 years of age, inclusive; and
b) Are capable of providing informed consent or have a legal representative authorized to give consent on behalf of the participant; and
c) Are capable of complying with study procedures, including fasting, blood sampling and lumbar puncture; and
d) Are participating in the Enroll-HD study; and
e) Will have had an Enroll-HD visit within two months of the Screening Visit.

For the Healthy Control group, participants eligible are persons who meet the following criteria:
a) Have no known family history of HD; or
b) Have known family history of HD but have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG < 36).

For the Early Pre-manifest HD group, participants eligible are persons who meet the following criteria:
a) Do not have clinical diagnostic motor features of HD, defined as Unified Huntington’s Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and
b) Have CAG expansion ≥ 40; and c. Have burden of pathology score, computed as (CAG – 35.5) × age, < 250.

For the Late Pre-manifest HD group, participants eligible are persons who meet the following criteria:

  • Do not have clinical diagnostic motor features of HD, defined as Unified Huntington’s Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and
  • Have CAG expansion ≥ 40; and
  • Have burden of pathology score, computed as (CAG – 35.5) x age, ≥ 250.

For Early Manifest HD group, participants eligible are persons who meet the following criteria:

  • Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
  • Have CAG expansion ≥ 40; and
  • Have Stage I or Stage II HD, defined as UHDRS Total Functional Capacity (TFC) scores between 7 and 13 inclusive.

For Moderate Manifest HD group, participants eligible are persons who meet the following criteria: 

  • Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
  • Have CAG expansion ≥ 40; and
  • Have Stage III HD, defined as UHDRS TFC scores between 3 and 6, inclusive.

For Advanced Manifest HD group, participants eligible are persons who meet the following criteria:

  • Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
  • Have CAG expansion ≥ 40; and
  • Have Stage IV HD, defined as UHDRS TFC scores between 0 and 2, inclusive.
  1.  

For all groups, participants are ineligible if they meet any of the following exclusion criteria:

  1. Use of investigational drugs or participation in a clinical drug trial within 30 days prior to Sampling Visit; or
  2. Current intoxication, drug or alcohol abuse or dependence; or
  3. If using any medications or nutraceuticals, the use of inappropriate (e.g., non prescribed) or unstable dose within 30 days prior to Sampling Visit; or
  4. Significant medical, neurological or psychiatric co-morbidity likely, in the judgment of the Site Principal Investigator, to impair participant’s ability to complete study procedures, or likely to reduce the utility of the samples and data for the study of HD; or
  5. Needle phobia, frequent headache, significant lower spinal deformity or major surgery; or
  6. Antiplatelet or anticoagulant therapy within the 14 days prior to Sampling Visit, including but not limited to: aspirin, clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban and apixaban; or
  7. Clotting or bruising disorder; or
  8. Screening blood test results more than 10% outside the lab’s normal range for the following: white cell count, neutrophil count, lymphocyte count, hemoglobin (Hb), platelets, prothrombin time (PT) and activated partial thromboplastin time (APTT), or any combination of blood test results that the Site Principal Investigator deems to be of clinical significance; or
  9. Screening blood test results for C-reactive protein (CRP)>2× upper limit of normal; or
  10. Predictable non-compliance as assessed by Site Principal Investigator; or
  11. Inability or unwillingness to undertake any of the study procedures; or
  12. Exclusion during history or physical examination, final decision to be made by the Site Principal Investigator; including but not limited to:

i. any reason to suspect abnormal bleeding tendency, e.g. easy bruising, petechial rash; or

ii. any reason to suspect new focal neurological lesion, e.g. new headache, optic disc swelling, asymmetric focal long tract signs; or

iii. any other reason that, in the clinical judgment of the Site Principal Investigator, it is felt that lumbar puncture performed per this protocol and associated manuals is unsafe without brain imaging.

m. Serious Adverse Event (SAE) related to study procedures during or following any previous HDClarity Sampling Visit (if applicable), or SAE related to any other lumbar puncture in the previous 12 months.

LOCATIONS

COUNTRIES

FRANCE

TRIAL SITE:
Centre Hospitalier Universitaire d’Angers

Address: Angers, France, 49100

CONTACT
Audrey Olivier
Tel: +33 241355615
Email:auolivier@chu-angers.fr

Recruiting

TRIAL SITE
Centre Hospitalier Universitaire de Bordeaux

Address: Bordeaux, France, 33000

CONTACT
Marie-Pierre Baudier
tel: +33 0675887726
email:mariepierre.baudier@chu-bordeaux.fr

Recruiting

GERMANY

TRIAL SITE:
George Huntington Institute

Address: Münster, Germany, 48149.

CONTACT
Svenja Aufenberg
Tel: +49-251-788-788-0
Email:svenja.aufenberg@ghi-muenster.de

Recruiting

TRIAL SITE: 
University Hospital Ulm

Address: Ulm, Baden-Württemberg, Germany, 89081

CONTACT
Olga Kuvarzina
tel: +49 731-500-63080
email: Olga.Kuvarzina@uniklinik-ulm.de

Recruiting

TRIAL SITE:
St Josef And Elisabeth Hospital

Address: Bochum, Germany, 44791.

CONTACT
Barbara Kaminski
Tel:+49 2345096405
Email:b.kaminski@klinikum-bochum.de

Recruiting

TRIAL SITE:
University Hospital of Erlangen

Address: Erlangen, Germany, 91054

CONTACT
Susanne Seifert
tel:+49 9131 85 44751
email: susanne.seifert@uk-erlangen.de

Recruiting

TRIAL SITE: 
Dresden University

Address:Dresden, Saxony, Germany, 01307

CONTACT
Marian Kollaske
tel: +49 351 458 11544
email:Marian.Kollaske@ukdd.de

Recruiting

TRIAL SITE: 
Kbo-Isar-Amper-Klinikum Taufkirchen (Vils)

Address: Taufkirchen (Vils), Germany, 84416

CONTACT
Michael Bachmaier
Tel: +49 08084-934-417
Email:michael.bachmaier@kbo.de

Recruiting

ITALY

TRIAL SITE:
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Address: Milan, Italy, 20133

CONTACT
Anna Castaldo
Tel: +39 0223942519
Email:anna.castaldo@istituto-besta.it

Active, Not Recruiting

TRIAL SITE: 
Lega Italiana Ricera Huntington

Address: Rome, Italy, 00185

CONTACT
Consuelo Ceccarelli
tel: +39 0644700887
email: consuelo.ceccarelli@lirh.it

Recruiting

POLAND

TRIAL SITE:
Instytut Psychiatrii i Neurologii w Warszawie (IPIN)

Address: Jana III Sobieskiego 9, 02-957 Warszawa, Polonia

CONTACT
Malgorzata Rowinska
tel: +48 698250623
Email:m.dusza.rowinska@gmail.com 

Active, Not Recruiting

SPAIN

TRIAL SITE:
Hospital de Sant Pau

Address: Barcelona, Spain, 08041

CONTACT
Arnau Puig Davi
tel: +34 649 14 23 60
email: apuigd@santpau.cat

Recruiting

TRIAL SITE: Associacion de Investigacion Sanitaria Bio-Cruces

Address:Plaza Cruces S/N | 48903 Barakaldo

CONTACT:
Marian Ángeles Acera Gil
tel: +34 94600636
email: aceramarian@gmail.com

Recruiting

TRIAL SITE:Ramón y Cajal Universitary Hospital

Address:M-607, Km. 9, 100, Fuencarral-El Pardo, 28034 Madrid, Spain

CONTACT:
Rocío López Pérez 
tel: +34 913368984
email: rocio.lopez.externo@salud.madrid.org

Recruiting

UNITED KINGDOM

TRIAL SITE:
Royal Devon & Exeter NHS Foundation Trust

Address: Exeter, Devon, United Kingdom, EX2 5DW

CONTACT
Julie Moss
Tel:+44( 0)1392 406979
Email:julie.moss10@nhs.net

Recruiting

TRIAL SITE: 
Glasgow Clinical Research Facility

Address: Glasgow, Scotland, United Kingdom, G51 4TF

CONTACT
Helen Bannister
Tel:+44( 0)141 232 7600
Email:helen.bannister@ggc.scot.nhs.uk

Recruiting

TRIAL SITE:
Birmingham Huntingtons Disease Clinic

Address: Birmingham, United Kingdom, B15 2 FG

CONTACT
Elsa Benn
Tel:
+44(0)121 301 2363  Email:e.benn@nhs.net

Recruiting

TRIAL SITE:
Cambridge University Hospitals NHS Foundation Trust

Address: Cambridge, United Kingdom, CB2 0PY

CONTACT
Katie Andresen   
Tel:+44(0)1223 331141    Email:kera2@cam.ac.uk

Recruiting

TRIAL SITE: 
Fife Health Board – Whyteman’s Brae Hospital

Address: Kirkcaldy, United Kingdom, KY1 2ND

CONTACT
Fleur Davey   
Tel:  +44(0)1383 623623    Email:fleurdavey@nhs.net

Active, Not Recruiting

TRIAL SITE:
Leeds Teaching Hospital Trust

Address: Leeds, United Kingdom, LS7 4SA

CONTACT
Naz Azam   
Tel: +44(0)113 392 4679 Email:naz.azam@nhs.net

Recruiting

TRIAL SITE:
The Walton Centre NHS Foundation Trust

Address: Liverpool, United Kingdom, L9 7LJ

CONTACT
Andrea Clyne
Tel:+44(0)151 525 3611
Email:andrea.clyne@thewaltoncentre.nhs.uk

Recruiting

TRIAL SITE: 
University College London Hospitals NHS Foundation Trust

Address: London, United Kingdom, NW1 2P

CONTACT
Opeyemi Kinyomi
email: o.kinyomi@ucl.ac.uk

 

Recruiting

TRIAL SITE:
Oxford University Hospitals NHS Foundation Trust

Address: Oxford, United Kingdom, OX3 9DU

CONTACT
Zara Skitt   
Tel:+44(0)1865234309
Email: zara.skitt@ouh.nhs.uk

Recruiting

TRIAL SITE:
University Hospitals Plymouth NHS Trust

Address: Plymouth, United Kingdom, PL6 5FP

CONTACT
Elizabeth Cray
Tel: +44(0)1752 439636
email: elizabethcray@nhs.net

Recruiting

TRIAL SITE:
North Bristol NHS Trust

Address: Bristol, United Kingdom, BS10 5NB

CONTACT:
Anya Soonderpersha
Tel:
+44(0)1174148242
email:anya.Soonderpershad@nbt.nhs.uk

Active, Not Recruiting

TRIAL SITE:
Cardiff University

Address: Cardiff, United Kingdom, CF24 4HQ

CONTACT
Alison Johnson  
Tel:+44( 0)2920746394   Email:alison.johnson@wales.nhs.uk

Recruiting

TRIAL SITE: St George’s University Of London

Address: London, United Kingdom, SW17 0RE

CONTACT: Hae-Ree Seo
Tel: +44(0)208 725 5375
email:HaeRee.Seo@stgeorges.nhs.uk

Recruiting

new FB feed (19)

dictionary:

phenoptype

Phenotype refers to an individual’s observable traits, such as height, eye color and blood type. A person’s phenotype is determined by both their genomic makeup (genotype) and environmental factors.

new FB feed (19)

dictionary:

oxidative seres

an imbalance between unstable molecules called “free radicals” and protective “antioxidants” in your body

new FB feed (19)

dictionary:

Metabolism & bioenergetics

describe how your body turns food into fuel and uses that energy to live. 

new FB feed (19)

dictionary:

Small Molecule

a tiny chemical compound, much smaller than big biological structures like proteins, that can easily travel inside our cells to act as medicine (like aspirin or ibuprofen), a building block (like glucose), or a signaling tool in the body, often taken as pills because they’re easy to absorb and distribute

 

new FB feed (19)

dictionary:

Nucleic acid

(DNA and RNA) are the essential information-carrying molecules in all life, acting like blueprints that store and transmit genetic instructions for building and operating cells, directing everything from growth to protein production, and passing traits from parents to offspring.

new FB feed (19)

dictionary:

SNP-single nucleotide polymorphisms

a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.

 
new FB feed (19)

dictionary:

at risk

You do not know if you carry the genetic mutation for HD gene 

 
new FB feed (19)

dictionary:

TFC-total functional capacity

A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity. 

 
new FB feed (19)

dictionary:

Double-blinded

 means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.

new FB feed (19)

dictionary:

Open label

A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.

new FB feed (19)

dictionary:

Gene therapy

a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.

new FB feed (19)

dictionary:

UHDRS- Unified Huntington Disease Rating Scale

A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD

new FB feed (19)

dictionary:

CAG repeat

The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD

new FB feed (19)

dictionary:

Wild-type

the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein

new FB feed (19)

dictionary:

Tolerabilty

How well a person can handle a treatment without having serious or uncomfortable side effects.

new FB feed (19)

dictionary:

Striatum

Part of the brain that  coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.

new FB feed (19)

dictionary:

Randomized allocation

A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.

new FB feed (19)

dictionary:

Radioligand

a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity

new FB feed (19)

dictionary:

Protein

Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.

new FB feed (19)

dictionary:

Premanifest / Prodromal

Prior to onset or diagnosis of movement symptoms.

new FB feed (19)

dictionary:

Placebo

A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.

new FB feed (19)

dictionary:

PK - Pharmacokinetics

The movement of drugs through the body

new FB feed (19)

dictionary:

PD - Pharmacodynamics

The body’s biological response to drugs

new FB feed (19)

dictionary:

PET scan

Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.

new FB feed (19)

dictionary:

Neuron

Brain cells that store and transmit information

new FB feed (19)

dictionary:

MRI

Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones 

new FB feed (19)

dictionary:

mHTT

Mutant huntingtin protein. The protein produced by the faulty HD gene.

new FB feed (19)

dictionary:

Manifest

after HD diagnosis, or when symptoms are already showing

new FB feed (19)

dictionary:

Longitudinal study

A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once

new FB feed (19)

dictionary:

HTT

one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15

new FB feed (19)

dictionary:

fMRI

functional MRI:As with MRI, a technique using powerful magnetic fields  but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes

new FB feed (19)

dictionary:

CSF - cerebrospinal fluid

A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.

new FB feed (19)

dictionary:

Efficacy

A measure of whether a treatment works or not

new FB feed (19)

dictionary:

ASO(Antisense oligonucleotides)

A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene

new FB feed (19)

dictionary:

Biomarker

a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable

new FB feed (19)

dictionary:

BDNF

Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.

new FB feed (19)

dictionary:

Allele

one of the two copies of a gene

new FB feed (19)

dictionary:

Plasma

Liquid component of the blood.

new FB feed (19)

dictionary:

Gene

The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.

new FB feed (19)

dictionary:

Phase

Clinical trial phases are different stages of research that assess the safety and effectiveness of a new medical treatment or intervention in humans.

Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring.